The biomarker pTau 217 is associated with Alzheimer’s disease pathology and can be detected in plasma, providing a minimally invasive option to support other diagnostic tests.
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
Congresssional Staffer Tours
Nelson Labs Celebrates 40 Years of Excellence in Science and Service
G2G Consulting Provides Updates from Washington D.C.
bioMérieux Recognized as Top 1% by S&P Global
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
E&I Ski Day 2025 Recap
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia